title: The incidence of inherited porphyrias in Europe.
abstract: Retrospective estimates of the prevalence of porphyrias have been reported but there has been no large scale prospective study of their incidence. The European Porphyria Network collected information prospectively over a 3 year period about the number of newly diagnosed symptomatic patients with an inherited porphyria (335 patients from 11 countries). Prevalence was calculated from the incidence and mean disease duration. The incidence of hepato-cellular carcinoma (HCC) in acute hepatic porphyria and the prevalence of patients with recurrent acute attacks of porphyria were also investigated. The incidence of symptomatic acute intermittent porphyria (AIP) was similar in all countries (0.13 per million per year; 95 % CI: 0.10 - 0.14) except Sweden (0.51; 95 % CI: 0.28-0.86). The incidence ratio for symptomatic AIP: variegate porphyria: hereditary coproporphyria was 1.00:0.62: 0.15. The prevalence of AIP (5.4 per million; 95 % CI: 4.5-6.3) was about half that previously reported. The prevalence of erythropoietic protoporphyria (EPP) was less uniform between countries and, in some countries, exceeded previous estimates. Fourteen new cases of HCC (11 from Sweden) were reported in patients with acute porphyria. Sixty seven patients (3 VP; 64 AIP: 53 females, 11 males) with recurrent attacks of acute porphyria were identified. The estimated percentage of patients with AIP that will develop recurrent acute attacks was 3-5 %. In conclusion, the prevalence of symptomatic acute porphyria may be decreasing, possibly due to improved management, whereas the prevalence of EPP may be increasing due to improved diagnosis and its greater recognition as a cause of photosensitivity.
authors.affiliation: Department of Medical Biochemistry and Immunology, University Hospital of Wales, Cardiff, CF14 4XW, UK.
authors.forename: George
authors.initials: G
authors.lastname: Elder
authors.forename: Pauline
authors.initials: P
authors.lastname: Harper
authors.forename: Michael
authors.initials: M
authors.lastname: Badminton
authors.forename: Sverre
authors.initials: S
authors.lastname: Sandberg
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Deybach
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D046349:Coproporphyria, Hereditary / Q000453:epidemiology; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D008113:Liver Neoplasms / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D000623:Porphobilinogen Synthase / Q000172:deficiency; D017118:Porphyria, Acute Intermittent / Q000453:epidemiology; D046350:Porphyria, Variegate / Q000453:epidemiology; D011164:Porphyrias / Q000453:epidemiology* / Q000235:genetics*; D017094:Porphyrias, Hepatic / Q000453:epidemiology; D011446:Prospective Studies; D046351:Protoporphyria, Erythropoietic / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000623:Porphobilinogen Synthase